ADAR and thyroid cancer: Finally, we relate the main thyroid cancer signaling pathways to ADAR1 isoform levels, and we provide evidence that pharmacological inhibition of A-to-I editing in thyroid cancer cells diminishes aggressiveness in vitro, highlighting RNA editing as an exciting subject for research into thyroid cancer mechanisms and treatment options.